GWENDOLYN SPANGLER: Open Payments
NPI 1003346412 · ROANOKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$290 in 14 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $290
Food & beverage: $290
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $82 |
| E.R. Squibb & Sons, L.L.C. | 3 | $69 |
| ABBVIE INC. | 3 | $50 |
| Alkermes, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
Products named: INGREZZA, COBENFY, VRAYLAR, VIVITROL, ABILIFY ASIMTUFII, INVEGA SUSTENNA, Veozah, ARISTADA.
Industry payments across VA — which companies pay providers there.
